Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02066402
View directory record Official record
Conditions
Bacterial Infections
Interventions
Tedizolid (BAY119-2631), Placebo Tedizolid (BAY119-2631), Linezolid, Placebo Linezolid
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
5
States / cities
Chula Vista, California • La Mesa, California • Oceanside, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

CBD-Microglia PET Study

NCT04398719
View directory record Official record
Conditions
CBD, Healthy
Interventions
[11C]PBR28, Low-dose lipopolysaccharide, Intradermal Capsaicin
Radiation · Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery

NCT02065245
View directory record Official record
Conditions
Frailty
Interventions
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs), Placebo, Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
60 Years to 95 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional

Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

NCT05104853
View directory record Official record
Conditions
Primary Biliary Cholangitis
Interventions
CNP-104, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Coronado, California • Lancaster, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)

NCT02650895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Efprezimod alfa, Saline
Biological · Drug
Lead sponsor
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood

NCT05979428
View directory record Official record
Conditions
Healthy Volunteers, Dyslipidaemia
Interventions
NNC0491-6075, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males

NCT00493311
View directory record Official record
Conditions
Fever
Interventions
IV Placebo, IV Acetaminophen, Reference Standard Endotoxin (RSE)
Drug · Biological
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 75 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease

NCT00783692
View directory record Official record
Conditions
Crohn's Disease
Interventions
vedolizumab, Placebo
Drug · Other
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Los Angeles, California • Montebello, California + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)

NCT02374398
View directory record Official record
Conditions
Blood Loss
Interventions
Tranexamic Acid, Aquamantys System, Control
Drug · Device · Other
Lead sponsor
Eastern Maine Medical Center
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bangor, Maine
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2Phase 3 Interventional

Prometa Pharmacotherapy for Methamphetamine Dependence

NCT00260481
View directory record Official record
Conditions
Drug Abuse, Drug Dependence
Interventions
Prometa, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2016 · Synced Oct 14, 2026, 5:58 AM EDT
Not listed Phase 2 Interventional

Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Treatment of COVID-19 Acute Respiratory Distress

NCT04905836
View directory record Official record
Conditions
Covid19
Interventions
COVI-MSC, Placebo
Biological · Drug
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Brandon, Florida • Sarasota, Florida • Boise, Idaho + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty

NCT03981419
View directory record Official record
Conditions
Postoperative Recovery
Interventions
GRF6021, Placebo
Biological · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 14, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

NCT01629667
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Tralokinumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
50 Years to 79 Years
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
21
States / cities
Phoenix, Arizona • La Jolla, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 14, 2026, 5:58 AM EDT
Recruiting Phase 3 Interventional

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Trontinemab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
55 Years to 80 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
12
States / cities
Irvine, California • Long Beach, California • Oakland, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional

A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

NCT00078611
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
63
States / cities
Oro Valley, Arizona • Tucson, Arizona • Anaheim, California + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

NCT06305793
View directory record Official record
Conditions
Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions
IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
Drug · Behavioral
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Suspended Phase 1Phase 2 Interventional

Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1

NCT06071767
View directory record Official record
Conditions
HIV-1-infection
Interventions
ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 14, 2026, 5:58 AM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Not applicable Interventional

The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients

NCT03938584
View directory record Official record
Conditions
Vitamin C Deficiency, Smoking, Surgery, Surgery--Complications, Wound, Wound Complication, Wound Infection, Wound Dehiscence, Wound of Skin, Mandible Fracture, Mandible Open Fracture, Mandible Closed Fracture, Mandibular Fractures, Ascorbic Acid Deficiency, Oxidative Stress, Inflammation
Interventions
Vitamin C, Placebo
Dietary Supplement · Other
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of Sedatives on Tobacco Use Disorder

NCT03813121
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
midazolam intravenous infusion, placebo intravenous infusion, ketamine intravenous infusion
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

NCT01285609
View directory record Official record
Conditions
Lung Cancer - Non Small Cell Squamous
Interventions
Ipilimumab, Placebo, Paclitaxel, Carboplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
33
States / cities
San Diego, California • West Haven, Connecticut • Boca Raton, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

NCT05819398
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Spesolimab i.v., Spesolimab s.c., Placebo matching Spesolimab i.v., Placebo matching Spesolimab s.c.
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
19
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 14, 2026, 5:58 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease

NCT02157714
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PRX002, Placebo
Drug · Other
Lead sponsor
Prothena Biosciences Limited
Industry
Eligibility
40 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
8
States / cities
Long Beach, California • New Haven, Connecticut • Boca Raton, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Oct 14, 2026, 5:58 AM EDT